Business Description
Laboratorios Farmaceuticos Rovi SA
ISIN : ES0157261019
Share Class Description:
XMAD:ROVI: Ordinary SharesCompare
Compare
Traded in other countries / regions
ROVI.SpainROVIe.UKROVI.AustriaLABFF.USA41L.GermanyROVI.Mexico IPO Date
2007-10-26Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.39 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.27 | |||||
| Interest Coverage | 330.22 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 13.57 | |||||
| Beneish M-Score | -2.23 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 27.2 | |||||
| 3-Year EBITDA Growth Rate | 40.1 | |||||
| 3-Year EPS without NRI Growth Rate | 40.4 | |||||
| 3-Year FCF Growth Rate | 103.3 | |||||
| 3-Year Book Growth Rate | 15.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.78 | |||||
| 9-Day RSI | 70.85 | |||||
| 14-Day RSI | 67.57 | |||||
| 6-1 Month Momentum % | 62.44 | |||||
| 12-1 Month Momentum % | 97.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 0.86 | |||||
| Cash Ratio | 0.13 | |||||
| Days Inventory | 366.72 | |||||
| Days Sales Outstanding | 65.86 | |||||
| Days Payable | 127.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.52 | |||||
| Dividend Payout Ratio | 0.4 | |||||
| 3-Year Dividend Growth Rate | 94.8 | |||||
| Forward Dividend Yield % | 1.52 | |||||
| 5-Year Yield-on-Cost % | 26.71 | |||||
| 3-Year Average Share Buyback Ratio | 2.2 | |||||
| Shareholder Yield % | 3.54 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.35 | |||||
| Operating Margin % | 26.55 | |||||
| Net Margin % | 20.53 | |||||
| FCF Margin % | 7 | |||||
| ROE % | 31.6 | |||||
| ROA % | 19.83 | |||||
| ROIC % | 28.38 | |||||
| ROC (Joel Greenblatt) % | 46.62 | |||||
| ROCE % | 36.81 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.2 | |||||
| PE Ratio without NRI | 26.17 | |||||
| Shiller PE Ratio | 56.82 | |||||
| Price-to-Owner-Earnings | 35.27 | |||||
| PEG Ratio | 0.46 | |||||
| PS Ratio | 5.39 | |||||
| PB Ratio | 8.17 | |||||
| Price-to-Tangible-Book | 8.71 | |||||
| Price-to-Free-Cash-Flow | 76.44 | |||||
| Price-to-Operating-Cash-Flow | 39.26 | |||||
| EV-to-EBIT | 19.88 | |||||
| EV-to-EBITDA | 17.9 | |||||
| EV-to-Revenue | 5.3 | |||||
| EV-to-FCF | 75.68 | |||||
| Price-to-Projected-FCF | 3.91 | |||||
| Price-to-Median-PS-Value | 1.81 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.05 | |||||
| Price-to-Graham-Number | 3.18 | |||||
| Price-to-Net-Current-Asset-Value | 17.71 | |||||
| Earnings Yield (Greenblatt) % | 5.03 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 21.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Laboratorios Farmaceuticos Rovi SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 829.509 | ||
| EPS (TTM) (€) | 3.244 | ||
| Beta | 0.49 | ||
| Volatility % | 22.87 | ||
| 14-Day RSI | 67.57 | ||
| 14-Day ATR (€) | 2.341989 | ||
| 20-Day SMA (€) | 81.4275 | ||
| 12-1 Month Momentum % | 97.9 | ||
| 52-Week Range (€) | 37.96 - 86.9 | ||
| Shares Outstanding (Mil) | 51.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Laboratorios Farmaceuticos Rovi SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Laboratorios Farmaceuticos Rovi SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Laboratorios Farmaceuticos Rovi SA Frequently Asked Questions
What is Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI)'s stock price today?
The current price of XMAD:ROVI is €85.00. The 52 week high of XMAD:ROVI is €86.90 and 52 week low is €37.96.
When is next earnings date of Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI)?
The next earnings date of Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI) is 2024-05-08.
Does Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI) pay dividends? If so, how much?
The Dividend Yield %  of Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI) is 1.52% (As of Today), Highest Dividend Payout Ratio of Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI) was 0.52. The lowest was 0.11. And the median was 0.3. The  Forward Dividend Yield % of Laboratorios Farmaceuticos Rovi SA(XMAD:ROVI) is 1.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers